Pharma BD Deal Intelligence
AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd.
2025 · Licensing/Option · $2.0B · Complete
Announcement Sentiment
95
Strongly positive
Outcome Score
70
Largely worked — most objectives met.
AstraZeneca licensed a pan-KRAS inhibitor from Jacobio Pharma for global development and commercialization.
Key facts
- Announced Feb 10, 2025
- Closed Dec 21, 2025
- Deal value $2.0B
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications KRAS-mutant cancers
- Key assets Pan-KRAS inhibitor
- Mechanism Pan-KRAS inhibitor
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals